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To date, genome instability is considered to be a common feature not only of tumor cells, but also of non-malignant cells of cancer 
patients, including peripheral blood lymphocytes (PBLs). The issue of the association between genome instability in tumor cells 
and PBLs, as well as of its relationship with tumor progression remains poorly understood. Aim: To evaluate the level DNA dam-
age in tumor cells and PBLs of endometrial cancer (EC) patients with regard to clinical and morphological characteristics of the 
patients. Materials and Methods: DNA damage was assessed in 106 PBLs samples and 42 samples of tumor cell suspension from 
EC patients by comet assay. PBLs from 30 healthy women were used as control. The level of DNA damage was expressed as the 
percentage of DNA in the comet tails (% tail DNA). Results: It was revealed that the amount of DNA damage in PBLs of EC patients 
was 2.2 times higher in comparison with that of healthy donors (8.3 ± 0.7 and 3.7 ± 0.4% tail DNA, respectively) (p < 0.05). In this 
study, no association between the levels of DNA damage in endometrial tumor cells and PBLs was observed (r = 0.11; p > 0.05). The 
amounts of DNA damage both in tumor cells and PBLs were not related to the degree of tumor differentiation as well as the depth 
of myometrial invasion, but depended on the body mass index (BMI) of EC patients: high level of lesions was observed in patients 
with elevated BMI values. Furthermore, the level of DNA damage in tumor cells was associated to familial aggregation of cancer 
and was significantly higher in endometrial cells from patients with family history of cancer vs that from EC patients with sporadic 
tumors (32.3 ± 2.9 and 22.8 ± 1.8% tail DNA, respectively) (p < 0.05). It was also found that for women who had high level of DNA 
damage in PBLs, the risk of EC was greater (odds ratio value of 3.5) compared to those with low level of such lesions. Conclusion: 
Genome instability that appears as an increased level of DNA damage in tumor cells and PBLs of EC patients is associated with 
BMI and family history of cancer and can reflect a predisposition to cancer.
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Today, it is well known that the formation and pro-
gression of malignant neoplasms are accompanied 
by extensive molecular genetic changes. The presence 
of various types of DNA damage and chromosomal 
alterations is a characteristic feature of tumor cells [1]. 
According to modern notions, such changes are associ-
ated with genomic instability of malignant cells and reflect 
the influence of exo- and endogenous DNA-damaging 
factors, as well as defects in the functioning of the DNA 
repair systems [1, 2]. Genome instability promotes the 
emergence of genetic diversity, clonal evolution of tumor 
cells and progression of the neoplastic process [3].
Modern studies indicate that endometrial carcinoma 
is characterized by the presence of microsatellite and 
chromosomal instability [4]. Moreover, endometrial 
cells are constantly exposed to the genotoxic influence 
of reactive oxygen species (ROS) resulting from meta-
bolic transformations of estrogens during the menstrual 
cycle [5]. The elevated ROS level leads to the appear-
ance of a highly mutagenic 8-oxo-7,8-dihydro-2'-de-
oxyguanosine, DNA breaks, apurin sites and chromo-
somal alterations [6]. Furthermore, genome instability 
of endometrial tumor cells may have hereditary origin, 
in particular due to germline mutations in the mismatch 
repair genes in the Lynch syndrome [7].
In recent years, numerous studies have been de-
voted to the problem of genome destabilization in ma-
lignant cells [8, 9]. However, today little is known about 
how the deregulation of genome integrity maintenance 
in carcinoma cells manifests at the systemic level, that 
is, on the structural and functional features of other cells 
in the body, including peripheral blood lymphocytes 
(PBLs). Meanwhile, in recent years, the issue of the 
possibility of using lymphocytes as surrogate markers 
(cells) that reflect the molecular genetic changes in the 
tumor is actively discussed [10–12].
A number of studies have shown that genome integ-
rity in the PBLs of patients with different forms of cancer 
is disturbed [13–18]. Our previous study has revealed 
that PBLs of endometrial cancer (EC) are characterized 
by strong genome destabilization, in particular impaired 
DNA repair, which is associated with family history of can-
cer [21]. However, the issue of the relationship between 
genome instability in PBLs and tumor cells, as well as its 
association with tumor progression and clinical charac-
teristics of patients with EC, remains insufficiently studied.
This study aims to analyze the association between 
DNA damage in PBLs and tumor cells of EC patients. 
In addition, the dependence of the degree of DNA dam-
age on the clinical and morphological characteristics 
of patients and its significance to the risk of EC is studied.
MATERIALS AND METHODS
A total of 106 newly diagnosed, previously un-
treated patients with EC stages I and II were recruited 
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tients had tumors of the female reproductive system, 
gastrointestinal tract and lungs (Table 2). For further 
analysis of DNA damage level in PBLs and tumor cells, 
a group of EC patients with family history of cancer 
was formed, which included women with clustering 
of the female reproductive system and/or other Lynch-
associated tumor incidence in their pedigrees [7].
There was no statistically significant difference 
in the amount of DNA damage between PBLs from 
EC patients with family history of cancer compared 
to those with no family history. However, it was found 
that the level of DNA damage in tumor cells from 
patients with family history of cancer significantly ex-
ceeded that in cells from patients with sporadic tumors 
(32.3 ± 2.9 and 22.8 ± 1.8% tail DNA, respectively) 
(p < 0.05) (Fig. 2).
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Fig. 2. DNA damage in PBLs and tumor cells of EC patients with 
regard to family history of cancer
In order to assess the association between DNA 
damage level in PBLs and EC risk, the OR value among 
matched case and control groups (30 EC patients 
and 30 healthy individuals) was calculated. According 
to the obtained data, the median (Me) of % tail DNA 
in PBLs was 3.7, on the basis of which all the examined 
women were divided into groups with high (> Me) and 
low (< Me) levels of DNA damage. It was found that for 
women who had high level of DNA damage in PBLs, 
the risk of EC was greater compared to those with low 
level of such lesions (OR value of 3.5) (Table 3).
Table 3. Association between DNA damage in PBLs and EC risk
Level of DNA  
damage
Group of examined women OR (95% CI)EC patients Controls
Low 11 10 3.5 (1.2–10.0)High 19 20
DISCUSSION
The issue of the occurrence and causes of genome 
instability in PBLs of cancer patients has been ac-
tively investigated over recent years. Results of seve-
ral studies indicate a significant destabilization of the 
genome in PBLs of cancer patients. In particular, high 
level of baseline DNA damage was detected in patients 
with malignant tumors of breast, ovary, prostate, lungs, 
esophagus, bladder and kidney [13–20]. A number 
of studies revealed the association between the level 
of DNA damage in PBLs and risk of cancer [19, 20].
It is believed that an increased level of DNA dam-
age in PBLs and malignant cells may be caused by in-
fluence of environmental genotoxic factors as well 
as substances released during metabolic processes 
in cancer patients [2]. Very often, the effect of such 
factors emerges through the action of ROS that, com-
bined with antioxidant system failure, leads to the de-
velopment of oxidative stress [6]. It is well-known that 
ROS are characterized by pronounced DNA-damaging 
properties. They can induce the appearance of single- 
and double-stranded DNA breaks, highly mutagenic 
8-oxo-7,8-dihydro-2'-deoxyguanosine and other 
nucleotide modifications. It should be noted that today 
the genotoxic influence of ROS is considered as one 
of the possible mechanisms of carcinogenesis. In fact, 
oxidative DNA damage caused by ROS is constantly 
detected in malignant neoplasms of various localiza-
tions [23].
It is supposed that the main sources of endogenous 
ROS are the reactions of cellular respiration, lipid 
peroxidation and inflammation. Along with the latter, 
the metabolic transformations of estrogens may have 
a strong influence on the development of genome in-
stability in PBLs and tumor cells in EC patients, since 
these processes are accompanied by the formation 
of genotoxic intermediates — catechol estrogens, 
quinones and semiquinones which can directly bind 
DNA, leading to the occurrence of apurinic sites, or en-
ter the redox reactions with ROS production [26–28].
It is possible that the high level of DNA damage 
in PBLs and tumor cells of EC patients with elevated 
BMI values may be associated with hormonal effects 
as far as adipose tissue is an important source of es-
trogen. In addition, elevated BMI values are related 
to increased level of circulating proinflammatory cy-
tokines (TNFα, IL-1, IL-6, etc.) that can induce ROS 
formation [29]. It is characteristic that Salinas et al. 
revealed an elevated level of oxidative stress mark-
ers in the blood of EC patients with an increased BMI 
value [30].
An increased level of DNA damage in tumor 
cells in EC patients with family history of cancer can 
be caused by hereditary defects in DNA repair genes 
and tumor suppressors [7, 31–33]. Furthermore, 
it is assumed that there are other molecular mecha-
nisms that determine hereditary predisposition to EC, 
which may also be associated with the development 
of genome instability [32, 33]. Thus, it was found that 
the risk of developing hormone-dependent tumors 
for the study. All EC patients underwent surgery 
at the gynecological oncology department of the Na-
tional Cancer Institute, Kyiv, Ukraine. The mean age 
of EC patients was 59.1 ± 1.6 years. The control group 
consisted of 30 healthy women, matched on age and 
menopausal status, with no previous or present his-
tory of cancer. All patients were thoroughly informed 
about the study that was approved by the Committee 
for Ethical Issues of the R.E. Kavetsky Institute of Ex-
perimental Pathology, Oncology and Radiobiology, 
National Academy of Sciences of Ukraine.
Morphological analysis of tumors was performed 
on haematoxylin and eosin stained sections. All pa-
tients had a histologically confirmed diagnosis of en-
dometrioid carcinoma. Information on family history 
of cancer was obtained through the personal interview 
based on a structured questionnaire.
Lymphocytes were isolated from venous blood 
by density centrifugation using Ficoll-Hypaque gradi-
ent. To obtain tumor single cell suspensions, tumor 
tissue was disrupted with a MEDI machine (Becton 
Dickinson). After disaggregation of the tissue, the cell 
suspensions were filtered to remove any tissue debris. 
The viability of PBLs and tumor cells was determined 
using the trypan blue exclusion test.
In order to evaluate baseline levels of DNA damage 
in PBLs and tumor cells, single cell gel electrophoresis 
assay (DNA comet assay) was performed as described 
previously by Olive [22]. A suspension of lymphocytes 
or tumor cells (1–2 × 105 cells/ml) was mixed with 1% 
low melting point agarose (Sigma-Aldrich) at 37 °C, and 
75 μl of this mixture was spread on slides precoated 
with 1% normal melting point agarose (Sigma-Aldrich). 
After solidification of the agarose, the slides were im-
mersed into lysis solution (2.5 M NaCl, 100 mM EDTA, 
10 mM Tris base, 10% DMSO, 1% Triton X-100, pH 10). 
Lymphocytes treated with 100 μM H2O2 for 5 min. 
at 4 °C were used as a positive control. The lysis was 
carried out in the dark for 1 h at 4 °C. Then, the slides 
were transferred to the electrophoresis chamber and 
incubated in alkaline solution (300 mM NaOH and 
1 mM EDTA, pH > 13) for 20 min. Electrophoresis 
was performed in the same solution at a voltage 
of 0,8 V/cm for 20 min. After electrophoresis, the 
slides were neutralized with 0,4 M Tris HCl solution 
for 10 min, washed in distilled water 2 times for 5 min, 
dried at 37 °C, stained with SYBR Green I and analyzed 
with a fluorescence microscope. A total of 50 micro-
graphs per slide were assessed using the CometScore 
software package (TriTek Corp.). The level of DNA 
damage was expressed as the percentage of DNA 
in the comet tails (% tail DNA).
Statistical analysis was performed using the 
Statistica 8.0 software package (StatSoft, Inc.). The 
Mann — Whitney U test was used to evaluate differences 
between groups of EC patients and healthy women. 
A p-value less than 0.05 was considered statistically 
significant. Relationship between variables was deter-
mined using Spearman’s rank correlation coefficient (r). 
Logistic regression was used to calculate odds ratios 
(OR) and 95% confidence intervals (CI) for the associa-
tion between DNA damage level in PBLs and EC risk.
RESULTS
Large inter-individual difference in the level of DNA 
damage in PBLs was observed in both healthy donors 
and EC patients. At the same time, the range of this 
parameter was wider in PBLs of EC patients (1.1–21.4% 
tail DNA) than that of control samples (1.2–9.2% tail 
DNA). On average, the level of DNA damage in PBLs 
of EC patients was 8.3 ± 0.7% tail DNA that was 
2.2 times higher in comparison with its degree in healthy 
donors (3.7 ± 0.4% tail DNA) (p < 0.05). Analysis of the 
level of DNA damage in malignant cells was carried out 
on tumor tissue samples of 42 EC patients (7 — well, 
19 — moderate and 16 — poorly differentiated tumors). 
It was revealed that EC cells are characterized by a pro-
nounced amount of DNA damage, which averaged 
26.4 ± 1.8% tail DNA with individual variations ranging 
from 3.3 to 62.9% tail DNA (Fig. 1).
Fig. 1. Representative micrographs of comets derived from 
PBLs of healthy individuals (a), EC patients (b) and endometrial 
carcinoma cells (c)
To determine the possibility of using lymphocytes 
as surrogate cells that reflect certain characteristics 
of malignant cells, a correlation analysis was performed 
between the levels of DNA damage in PBLs and endo-
metrial tumor cells. In this study, no association between 
these parameters was observed (r = 0.11; p > 0.05).
Comparison of the level of genome instability with 
clinical and morphological features of EC patients did 
not reveal the relationship between DNA damage in PBLs 
or tumor cells and the degree of tumor differentiation 
as well as the depth of myometrial invasion (Table 1). 
However, it was found that the level of DNA damage 
in both PBLs and tumor cells depends on the body mass 
index (BMI) of EC patients. Thus, individuals with BMI 
values above the median (> 34.1 kg/m2) had significantly 
higher levels of DNA damage than those with less obesity 
(< 34.1 kg/m2) (p < 0.05) (Table 1). Therefore, increased 
DNA damage in PBLs was observed in EC patients from 
obesity class I (BMI 31.0–35.9 kg/m2).
Table 1. Comparison of DNA damage in PBLs and tumor cells with clinical 
and morphological characteristics of EC patients
Characteristics
Level of DNA damage,
% tail DNA
PBLs Tumor cells
Degree of tumor 
differentiation
Well differentiated 8.8 ± 3.6 26.1 ± 1.8
Moderately differentiated 8.7 ± 0.9 25.2 ± 3.2
Poorly differentiated 7.8 ± 1.2 25.8 ± 2.0
Depth of myome-
trial invasion
< ½ 8.6 ± 1.3 24.7 ± 3.1
> ½ 8.2 ± 0.9 26.1 ± 2.4
BMI < Me 5.8 ± 0.7 22.0 ± 1.9
> Me 8.6 ± 1.2* 29.2 ± 2.4*
Note: *significantly different from EC patients with BMI < Me (p < 0.05).
Pedigree analysis of all the EC patients revealed 
the familial clustering of cancers in 37 cases (38.9%). 
Most often, first and second degree relatives of EC pa-
Table 2. Familial aggregation of tumors in EC patients
Degree of relationship
Tumors localization and their quantity in families, n (%)
Female reproductive system Gastrointestinal 
tract Lungs Others TotalEndometrium Ovary Breast
І (mother, father, sister, brother, children) 4 (5.4) 2 (2.7) 1 (1.4) 8 (10.7) 5 (6.8) 13 (17.5) 33 (45.6)
ІІ (aunt, uncle, grandmother, grandfather, nephew, niece) 3 (4.0) 2 (2.7) 7 (9.5) 9 (12.2) 1 (1.4) 19 (25.7) 41 (55.4)
Total number of relatives with malignant tumors 19 (25.7) 17 (22.9) 6 (8.2) 32 (43.2) 74 (100.0)
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depends on the polymorphism of the genes involved 
in the estrogen metabolism [34, 35]. According to San-
tos et al., some polymorphic variants of such genes 
can modulate the level of chromosomal instability 
in PBLs of cancer patients [35].
It should be noted that the issue of the underly-
ing causes of genome instability in cells of cancer 
patients remains open today. There is an opinion that 
genome instability can precede tumorigenesis as well 
as it may be the consequence of this process. Actu-
ally, the development of a malignant disease may en-
hance the level of pre-existing genome destabilization 
in non-malignant cells through the effect of genotoxic 
substances released by the tumor on adjacent tissues 
and distant organs [23–25].
In conclusion, the results of the study indicate 
a pronounced destabilization of the genome in PBLs 
and tumor cells of EC patients, which may reflect 
homeostasis disorders in these women. It was shown 
that in both PBLs and tumor cells, the level of DNA 
damage depends on the BMI of EC patients and in-
creases in cases with elevated values of this param-
eter. In addition, the dependence of the level of DNA 
damage in endometrial carcinoma cells on familial 
aggregation of cancers was detected: the amount 
of DNA lesions was higher in EC patients with family 
history of cancer. The presented data indicate the pos-
sibility of determining the risk of EC by DNA damage 
level in PBLs. Specifically, the high amount of baseline 
DNA damage in PBLs is associated with an increased 
risk of EC. Further studies of PBLs of cancer patients 
are needed in order to determine the role of genome 
instability of somatic non-malignant cells in the patho-
genesis of the malignant disease. It is equally impor-
tant to ascertain the possibility of using lymphocytes 
as surrogate cells that reflect the morphological and 
functional characteristics of tumor cells.
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